U.S. data is current through June 2018. All of the data comes from the U.S. Food and Drug Administration, except for the category Manufacturer Parent Company.
The Parent Company was added by ICIJ.
The parent company information is based on 2017 public records.
A software defect, relating to the motorized wedge functionality when using an elekta linear accelerator, can result in incorrect dose delivery to the patient. also, dose delivery in the wrong location may occur when using a elekta leksell headframe.
조치
A notification dated March 3, 2004 was sent to the customers. The notification gave recommendations for avoiding the problem and stated that updated software would be provided when it becomes available. Firm representatives made follow-up telephone calls to the consignees.